16+
Major trials tracked
Antibody-drug conjugates · Live ClinicalTrials.gov data
Trastuzumab deruxtecan (Enhertu) clinical trial pipeline
The timeline below tracks the 16 largest phase 2–4 trastuzumab deruxtecan trials on ClinicalTrials.gov by enrolment, 6 of them actively recruiting. The next phase 3 primary completion among them is expected Aug 2026. Refreshed daily — add up to four competitors to compare pipelines side by side.
4
Phase 3 trials
6
Actively recruiting
Aug 2026
Next phase 3 primary completion
4,534
Participants across trials
Daiichi Sankyo
Lead sponsor by trial count
trastuzumab deruxtecan (16)10 active2017–2035
trastuzumab deruxtecan
'17
'19
'21
'23
'25
'27
'29
'31
'33
'35
trastuzumab deruxtecan
A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)P2
DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)P2
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]P3
DAISYP2
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)P2
DG-03P2
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast CancerP2
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)P3
DG-06P2
Scalp Cooling in MBCP2
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)P2
Optimal Application Timing of ADC Drugs for Advanced Breast CancerP2
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)P3
TDXdoseP4
Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast CancerP2
MEGA-TACT-BC3P3
Upcoming readouts
8 ahead · trastuzumab deruxtecan
Select a trial to load its full ClinicalTrials.gov record.
Key trastuzumab deruxtecan trials
Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07195344 | TDXdose — Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally… | Phase 4 | Recruiting | Oct 2029 |
| NCT07060807 | A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | Phase 3 | Recruiting | Jul 2033 |
| NCT04704934 | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarci… | Phase 3 | Active, not recruiting | Aug 2026 |
| NCT07543536 | MEGA-TACT-BC3 — Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer | Phase 3 | Not yet recruiting | Apr 2029 |
| NCT03523585 | DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] | Phase 3 | Completed | Jun 2022 |
| NCT07657130 | Optimal Application Timing of ADC Drugs for Advanced Breast Cancer | Phase 2 | Recruiting | Jun 2026 |
| NCT04379596 | DG-03 — Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DEST… | Phase 2 | Recruiting | Jun 2027 |
| NCT06311214 | Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or… | Phase 2 | Recruiting | Mar 2028 |
| NCT04986579 | Scalp Cooling in MBC | Phase 2 | Recruiting | Jun 2028 |
| NCT07466303 | Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer | Phase 2 | Not yet recruiting | Feb 2028 |
| NCT03384940 | DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) | Phase 2 | Completed | Aug 2019 |
| NCT04132960 | DAISY — Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis | Phase 2 | Completed | Oct 2021 |
Related drug pipelines
FAQ
- How many clinical trials are running for trastuzumab deruxtecan?
- ClinicalTrials.gov lists more than 16 phase 2–4 trastuzumab deruxtecan trials. This page tracks the 16 largest by enrolment: 11 phase 2, 4 phase 3, and 1 phase 4 among them, with 6 actively recruiting. Updated daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare trastuzumab deruxtecan against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.